Civitas' inhaled L-dopa Parkinson's treatment passes Phase I

Civitas Therapeutics generated positive top line results in a Phase I trial of CVT-301, its inhaled version of L-dopa to treat Parkinson's disease-related tremors. The drug, which is ingested through a hand-held inhaler, reached sufficient levels that support "its therapeutic potential," the Chelsea, MA, company said. Civitas' test on healthy volunteers was also shown to be safe and well-tolerated at many different dose levels, the company said. Civitas believes that the 40-year-old L-dopa drug will better maintain peak L-dopa plasma concentration than the more common oral delivery, which is not absorbed right away and can lead to variable plasma levels as well as debilitating Parkinson's symptoms. A grant from The Michael J. Fox Foundation for Parkinson's Research helped cover the cost. Release | Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.